ReviewInfection & chemotherapy2026
Recommendations for Adult Pneumococcal Vaccination in Korea: 2026 Update Incorporating the 21-Valent Pneumococcal Conjugate Vaccine.
Review in Infection & chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 21-valent pneumococcal conjugate vaccine (PCV21; CAPVAXIVE; Merck Sharp & Dohme) is the first pneumococcal conjugate vaccine (PCV) specifically designed for adults, targeting serotypes that currently cause disease in this population. PCV21 includes 11 serotypes not contained in any other approved PCV (9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, and 35B), together with serotypes 3, 6A, 7F, 8, 10A, 11A, 12F, 19A, 22F, and 33F. PCV21 was approved by the Korean Ministry of Food and Drug Safety in August 27, 2025. The Adult Immunization Committee of the Korean Society of Infectious Diseases recommends one of the following options for all adults aged ≥65 years and for adults aged 19-64 years at increased risk of pneumococcal disease: a single dose of PCV21, a single dose of PCV20, or sequential PCV15 followed by PPSV23, with no stated preference among these options. When PCV21 or PCV20 is administered, no additional pneumococcal vaccination is required. Because PCV21 does not include serotype 4, in populations with a high incidence of serotype 4 disease, PCV20 alone or sequential PCV15 followed by PPSV23 may be preferentially considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.